A Phase 1 Multicenter Study Evaluating The Safety And Efficacy Of Mhc Class Ii-Restricted Mage-A3/A6 T-Cell Receptor Engineered T Cells (Kite-718) In Patients With Advanced Cancers.
JOURNAL OF CLINICAL ONCOLOGY（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要